title: pp32/PHAPI determines the apoptosis response of non-small-cell lung cancer.
abstract: During malignant transformation, cancer cells have to evade cell-intrinsic tumor suppressor mechanisms including apoptosis, thus acquiring a phenotype that is relatively resistant to clinically applied anticancer therapies. Molecular characterization of apoptotic signal transduction defects may help to identify prognostic markers and to develop novel therapeutic strategies. To this end we have undertaken functional analyses of drug-induced apoptosis in human non-small cell-lung cancer (NSCLC) cells. We found that primary drug resistance correlated with defects in apoptosome-dependent caspase activation in vitro. While cytochrome c-induced apoptosome formation was maintained, the subsequent activation of caspase-9 and -3 was abolished in resistant NSCLC. The addition of recombinant pp32/putative human HLA class II-associated protein (pp32/PHAPI), described as a putative tumor suppressor in prostate cancer, successfully restored defective cytochrome c-induced caspase activation in vitro. Conditional expression of pp32/PHAPI sensitized NSCLC cells to apoptosis in vitro and in a murine tumor model in vivo. Immunohistochemical analyses of tumor samples from NSCLC patients revealed that the expression of pp32/PHAPI correlated with an improved outcome following chemotherapy. These results identify pp32/PHAPI as regulator of the apoptosis response of cancer cells in vitro and in vivo, and as a predictor of survival following chemotherapy for advanced NSCLC.
authors.affiliation: Department of Medicine (Cancer Research), West German Cancer Center, University Hospital Essen, Essen, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Hoffarth
authors.forename: A
authors.initials: A
authors.lastname: Zitzer
authors.forename: R
authors.initials: R
authors.lastname: Wiewrodt
authors.forename: P S
authors.initials: PS
authors.lastname: Hähnel
authors.forename: V
authors.initials: V
authors.lastname: Beyer
authors.forename: A
authors.initials: A
authors.lastname: Kreft
authors.forename: S
authors.initials: S
authors.lastname: Biesterfeld
authors.forename: M
authors.initials: M
authors.lastname: Schuler
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D020169:Caspases / Q000378:metabolism*; D004789:Enzyme Activation; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D009687:Nuclear Proteins; D016601:RNA-Binding Proteins; D014183:Transplantation, Heterologous
chemical_list: C087425:ANP32A protein, human; D000970:Antineoplastic Agents; D047908:Intracellular Signaling Peptides and Proteins; D009687:Nuclear Proteins; D016601:RNA-Binding Proteins; D020169:Caspases